Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers-Reference-Cited by-同舟云学术

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers

Published:2010-07-27 Issue:22 Volume:116 Page:5161-5167
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kelly Catherine M.,Krishnamurthy Savitri,Bianchini Giampaolo,Litton Jennifer K.,Gonzalez-Angulo Ana M.,Hortobagyi Gabriel N.,Pusztai Lajos

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.25269/fullpdf

Reference16 articles.

1. Gene-expression signatures in breast cancer;Sotiriou;N Engl J Med.,2009

2. Commercialized multigene predictors of clinical outcome for breast cancer;Ross;Oncologist.,2008

3. Systematic review: gene expression profiling assays in early stage breast cancer;Marchionni;Ann Intern Med.,2008

4. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer;Paik;N Engl J Med.,2004

5. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer;Paik;J Clin Oncol.,2006

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nottingham prognostic x (NPx): a risk stratification tool in ER‐positive HER2‐negative breast cancer: a validation study;Histopathology;2024-06-13

2. Deciphering the Clinical Behaviour of Invasive Lobular Carcinoma of the Breast Defines an Aggressive Subtype;Cancers;2024-05-16

3. Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights;Cancers;2023-11-20

4. Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer;npj Breast Cancer;2023-06-08

5. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer;Breast Cancer Research and Treatment;2022-03-26